评估纳贝-紫杉醇联合铂类作为卵巢癌（OC）一线化疗的疗效和安全性。自2018年7月至2021年12月，对接受铂类联合纳贝-紫杉醇作为上皮性OC、输卵管癌或原发腹膜癌一线化疗的患者进行回顾性评估。主要结果为无进展生存期（PFS）。检查不良事件（AEs）。进行亚组分析。评估了72名患者（中位年龄54.5岁，范围20.0-79.0岁），包括12名接受新辅助治疗和60名接受初级手术后随后化疗。中位随访时间为25.6个月，整体患者群中的中位无进展生存期为26.7（95％置信区间[CI] = 24.0-29.3）个月。在新辅助亚组中，中位PFS为26.7（95％CI = 22.9-30.5）个月，而在初级手术亚组中为30.1（95％CI = 23.1-37.1）个月。27名患者接受了纳贝-紫杉醇加卡铂治疗，中位PFS为30.3（95％CI =不可用[NA] -NA）个月。最常见的3-4级AE包括贫血（15.3％）、白细胞减少（11.1％）和中性粒细胞减少（20.8％）。未发生与药物相关的过敏反应。纳贝-紫杉醇加铂类作为OC一线治疗，具有良好的预后，并且对OC患者耐受性良好。©2023年。 亚洲妇科肿瘤学会，韩国妇科肿瘤学会和日本妇科肿瘤学会。

To evaluate the effectiveness and safety of nab-paclitaxel plus platinum as first-line chemotherapy for ovarian cancer (OC).Patients administered platinum combined with nab-paclitaxel as first-line chemotherapy for epithelial OC, fallopian tube cancer, or primary peritoneal cancer from July 2018 to December 2021 were retrospectively evaluated. The primary outcome was progression-free survival (PFS). Adverse events (AEs) were examined. Subgroup analysis was performed.Seventy-two patients (median age, 54.5 years; range, 20.0-79.0 years) were evaluated, including 12 and 60 administered neoadjuvant therapy and primary surgery with subsequent chemotherapy, respectively. The median follow-up duration was 25.6 months, and the median PFS was 26.7 (95% confidence interval [CI]=24.0-29.3) months in the whole patient population. In the neoadjuvant subgroup, the median PFS was 26.7 (95% CI=22.9-30.5) months vs. 30.1 (95% CI=23.1-37.1) months in the primary surgery subgroup. Twenty-seven patients were administered nab-paclitaxel plus carboplatin and had a median PFS of 30.3 (95% CI=not available [NA]-NA) months. The commonest grade 3-4 AEs included anemia (15.3%), white blood cell decreased (11.1%), and neutrophil count decreased (20.8%). No drug-related hypersensitivity reactions occurred.Nab-paclitaxel plus platinum as first-line treatment in OC was associated with a favorable prognosis and was tolerable in patients with OC.© 2023. Asian Society of Gynecologic Oncology, Korean Society of Gynecologic Oncology, and Japan Society of Gynecologic Oncology.